#Canada #Cambridge #ALS #NeuroSense #PrimeC

NeuroSense Enhances Its Submission for ALS Treatment in Canada

NeuroSense Therapeutics Ltd., a clinical biotechnology enterprise focused on neurodegenerative diseases, has announced significant updates to its submission to Health Canada concerning PrimeC, their lead investigational therapy for amyotrophic lateral sclerosis (ALS). With a fresh analysis of the neurofilament light chain (NfL) data now part of the application, this marks a pivotal step toward obtaining the first marketing authorization for PrimeC, a development eagerly awaited by a significant portion of the Canadian ALS community.

Expanded Data Submission

The newly incorporated NfL analysis seeks to strengthen the evidence surrounding PrimeC's efficacy, which targets a group of approximately 4,000 Canadians currently living with ALS. According to the company's revised timeline, the new submission deadline is set for March 2027, allowing ample time for the inclusion of this critical data. The National Agency has confirmed that the adjusted schedule poses no concerns, providing reassurance amid the ongoing preparations.

Following the completion of the pre-submission procedure, the company aligned with Health Canada regarding the content of the proposed application. The upgraded package will integrate key findings from the Phase 2b PARADIGM trial results previously published in JAMA Neurology along with new insights drawn from the NfL analysis. This will culminate in a more comprehensive body of evidence intended to support the regulatory review process.

Positive Clinical Findings

Early results show that participants who received PrimeC experienced a more significant reduction in NfL levels compared to those on placebo. Notably, a more pronounced effect was noted in individuals who displayed a higher functional status at the outset, emphasizing the potential of PrimeC to deliver beneficial outcomes early in the disease progression. Further statistic reviews are currently being pursued to refine these findings further.

As the anticipated submission moves forward, Health Canada is expected to conduct a standard review process that typically spans around 300 calendar days. If approved, PrimeC's authorization would provide a vital therapeutic avenue for the growing population of ALS patients in Canada, where around 1,000 new cases are diagnosed annually.

Future Directions for NeuroSense

Alon Ben-Noon, CEO of NeuroSense, expressed optimism about the forthcoming application, stating, “The inclusion of the neurofilament light chain analysis enhances the evidence base from which Health Canada will appraise PrimeC's potential benefits for individuals diagnosed with ALS. Canada represents our most immediate opportunity for patient access, and we are committed to submitting a robust application.”

Parallel to addressing requirements in Canada, NeuroSense is also gearing up for its Phase 3 PARAGON trial with the U.S. FDA, setting the stage for further advancement in the clinical landscape of ALS treatments.

About NeuroSense Therapeutics

NeuroSense Therapeutics specializes in crafting novel therapies for severe neurodegenerative conditions, including ALS and Alzheimer's disease. Their flagship product, PrimeC, consists of an innovative oral formulation that merges two FDA-approved medications, ciprofloxacin and celecoxib. This combination aims to target the biological mechanisms driving neurodegeneration, offering hope for mitigating disease progression.

Understanding ALS

Amyotrophic lateral sclerosis (ALS) is a devastating illness characterized by progressive paralysis that frequently culminates in mortality within three years from the onset of symptoms. The frequency of ALS diagnoses continues to rise, with projections indicating a 24% increase among affected individuals by 2040 in the U.S. and EU regions. This troubling trend highlights the urgent need for effective treatment options.

For further insights into ongoing research and developments, interested parties are encouraged to explore more about NeuroSense Therapeutics via their website and social media platforms. They frequently share vital information that may be of particular interest to investors, ensuring transparency and continued engagement with the community.